Pete O’heeron Acquires 8,500 Shares of FibroBiologics, Inc. (NASDAQ:FBLG) Stock

FibroBiologics, Inc. (NASDAQ:FBLG) CEO Pete O’heeron bought 8,500 shares of the business’s stock in a transaction on Monday, August 12th. The stock was purchased at an average cost of $1.91 per share, for a total transaction of $16,235.00. Following the transaction, the chief executive officer now owns 6,056,647 shares of the company’s stock, valued at $11,568,195.77. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

FibroBiologics Trading Down 7.1 %

Shares of FBLG stock traded down $0.14 on Monday, hitting $1.83. The stock had a trading volume of 278,221 shares, compared to its average volume of 177,141. The firm has a 50 day moving average of $5.50. FibroBiologics, Inc. has a 1 year low of $1.77 and a 1 year high of $55.00.

FibroBiologics (NASDAQ:FBLG) last released its earnings results on Tuesday, May 14th. The company reported ($0.27) earnings per share for the quarter. Research analysts predict that FibroBiologics, Inc. will post -0.47 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Mercer Global Advisors Inc. ADV acquired a new position in shares of FibroBiologics during the second quarter worth about $51,000. Rhumbline Advisers purchased a new position in FibroBiologics in the second quarter worth approximately $115,000. Bank of New York Mellon Corp acquired a new position in FibroBiologics during the 2nd quarter worth approximately $342,000. Fund Evaluation Group LLC purchased a new stake in shares of FibroBiologics in the 2nd quarter valued at approximately $5,265,000. Finally, Cahaba Wealth Management Inc. acquired a new stake in shares of FibroBiologics in the 2nd quarter valued at $73,000.

About FibroBiologics

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.